When used as post-exposure prevention (PEP) of mpox, the vaccine Jynneos had an adjusted vaccine effectiveness (VE) of 88.8%, and vaccination can be protective against the virus up to 7 weeks following exposure, according to a study published yesterday in Eurosurveillance.
The real-world prospective cohort study to assess VE of one vaccine dose given as PEP took place in Madrid from May 17 to August 15, 2022, among close contacts of confirmed mpox cases. The vaccine was offered up to 14 days post exposure, preferentially in the first 4 days, the authors said.

Overall, the VE was 88.8% (95% confidence interval [CI], 76.0 to 94.7). Results were divided among close contacts who shared a living space with the index patient, and those who did not. VE was 93.6% for non-cohabitants and 88.6% for cohabitants.
"We found that breakthrough infections did not exhibit severe symptoms (none required hospitalization)," the authors said. "Furthermore, there were fewer symptoms, a reduction in general symptoms of at least 18.1% and a reduction in polysymptomatic disease of at least 26.7% in vaccinated cases compared with unvaccinated cases.”
The authors of the study said this real-world data supports PEP for controlling mpox outbreaks.